Filtered By:
Specialty: Hematology
Source: Thrombosis and Haemostasis

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 528 results found since Jan 2013.

Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
Abstract Recent anticoagulants for stroke prevention in AF have been tested in active comparator controlled studies versus warfarin using two designs: double-blind, double-dummy and prospective randomised, open blinded endpoint (PROBE). The former requires elaborate procedures to maintain blinding, while PROBE does not. Outcomes of double-blind and PROBE designed studies of novel anticoagulants for AF, focusing on warfarin controls, were explored. Major, Phase III warfarin-controlled trials for stroke prevention in AF were identified. Odds ratios (ORs) of key outcomes for active comparators versus VKA and event ra...
Source: Thrombosis and Haemostasis - January 24, 2013 Category: Hematology Authors: O'Neil WM, Welner SA, Lip GY Tags: Thromb Haemost Source Type: research

Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.
In conclusion, in patients with AF and high thromboembolic risk after stent implantation, use of OAC was independently associated with decreased risk of subsequent death/stroke/systemic TE, suggesting that OAC should be systematically used in this patient population. PMID: 23846210 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 11, 2013 Category: Hematology Authors: Bernard A, Fauchier L, Pellegrin C, Clementy N, Saint Etienne C, Banerjee A, Naudin D, Angoulvant D Tags: Thromb Haemost Source Type: research

Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial.
In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for "any clinically relevant bleeding" in anticoagulated patients with AF, whilst the CHADS2 and CHA2DS2-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS2 or CHA2DS2-VASc scores should not be used. PMID: 24048467 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 19, 2013 Category: Hematology Authors: Apostolakis S, Lane DA, Buller H, Lip GY Tags: Thromb Haemost Source Type: research

Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta-analysis.
CONCLUSION: Mortality in patients treated by thrombolytic therapy for valve prosthesis thrombosis is significantly lower than in patients treated surgically. As we cannot yet ascertain whether this difference is due to the treatment alone, more studies now are necessary to further clarify these findings. This article is protected by copyright. All rights reserved. PMID: 24698327 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 2, 2014 Category: Hematology Authors: Castilho FM, Sousa MR, Mendonça AL, Ribeiro AL, Cáceres-Lóriga FM Tags: J Thromb Haemost Source Type: research

Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
In conclusion, in routine care of patients with non-valvular atrial fibrillation, dabigatran treatment resulted in improved health outcomes compared with warfarin. PMID: 26446507 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S Tags: Thromb Haemost Source Type: research

Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
CONCLUSION: A limited number of prediction models is available that predict intracranial hemorrhage or major bleeding in patients on antiplatelet therapy. Methodological quality of the models varied, but was generally low. Predictive performance in patients with cerebral ischemia was poor. In order to reliably predict the risk of bleeding in patients with cerebral ischemia, development of a prediction model according to current methodological standards is needed. This article is protected by copyright. All rights reserved. PMID: 26563743 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 12, 2015 Category: Hematology Authors: Hilkens NA, Algra A, Greving JP Tags: J Thromb Haemost Source Type: research

Patient values and preferences for antithrombotic therapy in atrial fibrillation. A Narrative Systematic Review.
In conclusion, patients' values and preferences for SPAF antithrombotic therapy are heterogeneous and there is no substitute for directly clarifying patients' individual values and preferences. Research using choice modelling and tools to help clinicians and patients clarify their SPAF therapy values and preferences are needed. PMID: 28276567 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 8, 2017 Category: Hematology Authors: Loewen PS, Ji AT, Kapanen A, McClean A Tags: Thromb Haemost Source Type: research

Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry.
CONCLUSION:  Presence, but not extent, of CAD was an independent risk factor of the composite thromboembolic endpoint beyond the components already included in the CHA2DS2-VASc score. Consequently, we suggest that significant angiographically proven CAD should be included in the vascular disease criterion in the CHA2DS2-VASc score. PMID: 30419601 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 12, 2018 Category: Hematology Authors: Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Bøtker HE, Lip GYH, Maeng M Tags: Thromb Haemost Source Type: research

Increased Leucocyte-Platelet Complex Formation in Recently Symptomatic versus Asymptomatic Carotid Stenosis Patients and in Micro-emboli Negative Subgroups.
CONCLUSION: These data add to the evidence that leucocyte-platelet complex formation/platelet activation is increased in recently symptomatic versus asymptomatic patients, and may contribute to the pathogenesis of first and subsequent strokes in carotid stenosis patients, including those who are MES negative. PMID: 30769362 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 15, 2019 Category: Hematology Authors: Murphy SJX, Lim ST, Kinsella JA, Tierney S, Egan B, Feeley TM, Murphy SM, Walsh RA, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, Cox D, Moran N, Hamilton G, McCabe DJH Tags: Thromb Haemost Source Type: research

von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
DISCUSSION:  VWF:Ag expression, a marker of endothelial ± platelet activation, is enhanced in recently symptomatic versus asymptomatic carotid stenosis patients, including in MES-ve patients, and decreases with ADAMTS13 activity over time following atherosclerotic TIA/ischemic stroke. PMID: 32932544 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 14, 2020 Category: Hematology Authors: Murphy SJX, Lim ST, Hickey F, Kinsella JA, Smith DR, Tierney S, Egan B, Feeley TM, Murphy SM, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, O'Donnell JS, O'Sullivan JM, Hamilton G, McCabe DJH Tags: Thromb Haemost Source Type: research

Considerations for use of direct oral anticoagulants in arterial disease
Res Pract Thromb Haemost. 2021 May 28;5(4). doi: 10.1002/rth2.12502. eCollection 2021 May.ABSTRACTCardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source,...
Source: Thrombosis and Haemostasis - June 7, 2021 Category: Hematology Authors: Deborah M Siegal Sonia S Anand Source Type: research

Circulating cytokines and growth factors in acute cerebral large vessel occlusion - association with success of endovascular treatment
In conclusion, this study provides first evidence that cytokines and growth factors are potential effectors in patients undergoing MT for the treatment of acute ischemic stroke.PMID:34225367 | DOI:10.1055/a-1544-5431
Source: Thrombosis and Haemostasis - July 5, 2021 Category: Hematology Authors: Gerrit M Grosse Christopher Werlein Nicole Blume Omar Abu-Fares Friedrich Goetz Maria M Gabriel Johanna Ernst Andrei Leotescu Hans Worthmann Mark P K ühnel Danny Jonigk Christine Falk Karin Weissenborn Ramona Schuppner Source Type: research

Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis
CONCLUSIONS: Patients with morbid obesity on DOACs had similar risks of stroke/systemic embolism, lower rates of recurrent VTE and major bleeding events compared to those on VKAs. However, the certainty of evidence was low given that studies were mostly observational with high risk of confounding.PMID:34399433 | DOI:10.1055/a-1588-9155
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Tzu-Fei Wang Marc Carrier Karine Fournier Deborah M Siegal Gr égoire Le Gal Aur élien Delluc Source Type: research